Japan's figure skating icon Yuzuru Hanyu performed his ice show on Friday in his native Miyagi Prefecture, commemorating the 14th anniversary of the devastating March 11 earthquake and tsunami that ...

Bullish option flow detected in Novavax (NVAX) with 10,455 calls trading, 2x expected, and implied vol increasing over 6 points to 78.51%. 3/14 ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland, said ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...

Shares of Novavax Inc. NVAX shed 5.52% to $7.87 Monday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 2.64% to 18,350 ...